FIELD: biotechnology.
SUBSTANCE: described is a method for determining the status of prostate cancer, including the stage of: a) determining the presence or absence of prostate cancer and/or the status of progression of prostate cancer in a sample based on a gene expression profile including the level of expression of at least two variants of phosphodiesterase 4D (PDE4D), selected from the group consisting of PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D7, PDE4D8 and PDE4D9, wherein none of the PDE4D variants are used as a standard gene, wherein the method includes, at stage (a), (a2) determination of the level of expression of the standard gene in the sample; (a3) normalisation of the level of expression of the PDE4D variants measured at stage (a), by the level of expression of the standard gene, resulting in the normalised gene expression profile. Also described is a method for determining the status of prostate cancer, including the stage of: a) determining the presence or absence of the TMPRSS2-ERG hybrid gene or the level of expression of the ERG transcription factor in a sample based on a gene expression profile including the level of expression of at least two variants of phosphodiesterase 4D (PDE4D), selected from the group consisting of PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D7, PDE4D8 and PDE4D9, wherein none of the PDE4D variants are used as a standard gene, wherein the method includes, at stage (a), (a2) determination of the level of expression of the standard gene in the sample; (a3) normalisation of the level of expression of the PDE4D variants measured at stage (a), by the level of expression of the standard gene, resulting in the normalised gene expression profile.
EFFECT: invention expands the range of methods for determining the status of prostate cancer.
7 cl, 13 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RISK ASSESSMENT BASED ON EXPRESSION OF HUMAN 4D PHOSPHODIESTERASE OPTION 7 | 2017 |
|
RU2766885C2 |
| PHOSPHODIESTERASE 4D7 AS PROSTATE CANCER MARKER | 2010 |
|
RU2651474C2 |
| PHOSPHODIESTERASE 4D7 AS MARKER FOR AGGRESSIVE HORMONE-SENSITIVE PROSTATE CANCER | 2010 |
|
RU2575076C2 |
| PREOPERATIVE RISK STRATIFICATION BASED ON PDE4D7 AND DHX9 EXPRESSION | 2019 |
|
RU2793635C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| ALLELE SNP41 OF GENE PDE4D, ITS APPLICATION FOR PREDICTION OF INDIVIDUAL PROPENSITY FOR STROKE IN RUSSIAN POPULATION, APPLICATION OF MOLECULAR-GENETIC MARKER OF INDIVIDUAL PROPENSITY FOR STROKE AND METHOD FOR PREDICTION OF INDIVIDUAL PROPENSITY FOR STROKE | 2010 |
|
RU2422523C1 |
| METHODS FOR PROSTATE CANCER PREDICTION | 2016 |
|
RU2721916C2 |
| POLYPEPTIDE WITH PHOSPHODIESTERASE ENZYMATIC ACTIVITY | 1998 |
|
RU2272841C2 |
| BIOMARKERS | 2005 |
|
RU2429297C2 |
| BIOMARKER | 2005 |
|
RU2385944C2 |
